A reference work, not a recommendation to use: this profile describes mechanism and evidence and does not replace medical advice. The claims come from marketing and forums and are tested here, not endorsed.

Mechanism of action

Evidence map: Piracetam

Each line stands for a published finding; line style and color show where it comes from. The filter hides weaker evidence levels. Sources: see references.

Piracetam is chemically derived from GABA, but no single receptor through which it acts is known. A review traces the many described effects back to a possible restoration of membrane fluidity and names effects on cholinergic and glutamatergic transmission, on seizure threshold, and on microcirculation [1]. The group around Müller describes a rather nonspecific physicochemical mechanism: piracetam attaches to the polar head groups of phospholipids, and this effect is stronger in membranes of aged brains than in young ones [2].

In the crystal structure of the ligand-binding domain of the AMPA receptor subunits GluA2 and GluA3, piracetam binds at several sites on the dimer interface, each with only low occupancy, and thus differently from aniracetam [3]. In old but not young mice, two weeks of treatment raised the density of muscarinic acetylcholine receptors in the frontal cortex by about 30–40% [4] and the density of NMDA receptors by about 20% [5]. In cell culture, piracetam improved the mitochondrial membrane potential and ATP production after oxidative stress; in mice, a similar effect was seen mainly in brain cells of old animals [6]. These findings come predominantly from one research group and were obtained in models with previously damaged or aged tissue.

Outside the brain, piracetam inhibits platelet aggregation and acts as an antithrombotic in vivo [7]; it is also said to reduce the adhesion of erythrocytes to the vascular endothelium [1]. Clinically, a Cochrane review showed a benefit in dementia or cognitive impairment only in the global clinical impression, not in specific cognitive tests [8]; a more recent meta-analysis found no significant difference from placebo for memory [9]. In acute ischemic stroke, piracetam brought no benefit [10][11]. In progressive myoclonus epilepsy, it clearly improved myoclonus in a small randomized trial [12].

Assigned to the site of action NMDA receptor (GluN1/GluN2B) in the postsynaptic membrane of a dendritic spine; not drawn in its figure: only changed receptor numbers (mice).

Targets

TargetTypeActionKey dataEvidence
Phospholipid membranes (polar head groups)OtherBinding Laboratory[2]
AMPA receptor GluA2/GluA3 (ligand-binding domain, dimer interface)ReceptorBindingseveral binding sites with low occupancy (crystal structure) Laboratory[3]
Muscarinic acetylcholine receptors (frontal cortex)ReceptorExpression ↑receptor density +30–40% (old mice), no effect in young ones Animal study[4]
NMDA receptorReceptorExpression ↑receptor density +20% (old mice) Animal study[5]
Mitochondrial functionOtherActivatoreffective at 100–1000 µM (PC12 cells after oxidative stress) Animal study[6]
Platelet aggregationOtherInhibitor Human, non-randomised[7]

Effect profile

Which signaling systems the compound affects according to current data. ↑ enhanced, ↓ dampened, ≈ modulated, ○ no effect; dots = evidence level.

  • Dopamineno data
  • Noradrenalineno data
  • Serotoninno data
  • Acetylcholine↑ · more muscarinic receptors in the cortex of old, not young, mice[4]
  • Glutamate · AMPAmodulated · weak binding to the dimer interface of the AMPA receptor binding domain (crystal structure)[3]
  • Glutamate · NMDA↑ · NMDA receptor density raised by about 20% in old mice[5]
  • GABAno data
  • Histamineno data
  • Orexinno data
  • Adenosineno data
  • Opioidsno data
  • Melatoninno data
  • Neurotrophinsno data
  • Blood flowmodulated · inhibits platelet aggregation; review of laboratory and clinical data[1][7]
  • Nitric oxideno data
  • Energy metabolism↑ · mitochondrial function improved after oxidative stress (cell culture, old mice)[6]
  • Insulin · glucoseno data
  • Inflammation · oxidativeno data
  • Stress axisno data
  • Testosterone axisno data
  • Endocannabinoidsno data
  • Autophagy · senescenceno data
  • Immune systemno data
  • Lipid metabolismno data
  • Coagulation · fibrinolysisno data
  • Methylationno data

Human studies

  • Cochrane review of dementia and cognitive impairment

    systematic review of randomized, placebo-controlled trials · Patients: dementia or cognitive impairment · more than one day (inclusion criterion)

    Measured: global clinical impression, cognitive tests

    Result: Global improvement more frequent (odds ratio 3.55; 95% CI 2.45–5.16, fixed-effects model); effects on cognition inconclusive.[8]

    Human, randomised

  • Meta-analysis of memory in impairment

    systematic review and meta-analysis of controlled trials · Patients: adults with memory impairment · n = 886 · 18 studies, varying

    Measured: memory performance

    Result: No significant difference from placebo (SMD 0.75; 95% CI −0.19 to 1.69; I² 96%).[9]

    Human, randomised

  • Cochrane review of acute ischemic stroke

    systematic review of randomized trials · Patients: acute ischemic stroke · n = 1002 · start within three days

    Measured: death, dependency, functional outcome

    Result: Nonsignificantly more deaths after one month (about +31%), no trend after adjusting for stroke severity; no difference in functional outcome.[10]

    Human, randomised

  • Progressive myoclonus epilepsy (Unverricht-Lundborg)

    RCT, double-blind, crossover, placebo-controlled · Patients: Unverricht-Lundborg disease · n = 20 · 6 weeks (treatment phases of 2 weeks each)

    Measured: total score on a myoclonus scale

    Result: Significant improvement, with a clear dose-response relationship; well tolerated.[12]

    Human, randomised

  • Verbal learning in healthy people

    double-blind; randomization and control condition not described in the abstract · healthy · 14 days

    Measured: verbal learning (word lists)

    Result: No effect after 7 days, better verbal learning after 14 days.[13]

    Human, randomised

  • Scopolamine model in healthy people

    double-blind, crossover (Latin square) · healthy · n = 26 · Single doses on seven occasions

    Measured: memory and information processing after scopolamine

    Result: Aniracetam attenuated the scopolamine deficits; the effects of the other treatments, including piracetam, were around chance level.[14]

    Human, randomised

  • Hypoxia model in healthy people

    RCT, double-blind, placebo-controlled, crossover · healthy · n = 18 · Single doses one week apart

    Measured: EEG vigilance, psychometrics under brief oxygen deprivation

    Result: The hypoxia-induced drop in EEG vigilance and the psychometric deterioration were attenuated.[15]

    Human, randomised

Risks and warnings

  • Inhibition of platelet aggregation

    Piracetam inhibits platelet aggregation and acts as an antithrombotic [7]; theoretically relevant with a bleeding tendency. In the large stroke trial PASS, bleeding-related events were equally frequent under piracetam and placebo [11].

    Human, non-randomised

  • Mortality in acute stroke

    Nonsignificant trend toward more deaths after one month, probably explained by unequal stroke severity at the start of the studies [10][11].

    Human, randomised

  • Tolerability

    Overall well tolerated in studies in patients, with side effects in the myoclonus trial rare, mild, and transient [12]; in PASS, side effects were similarly frequent as under placebo [11].

    Human, randomised

Interactions

  • Anticoagulants and antiplatelet agents: Because of its own inhibition of platelet aggregation [7], an additive effect is conceivable; no interaction study was found in the sources checked.

Fact check: common claims

  • not supported

    “Piracetam improves memory and concentration in healthy people”

    Only small, old studies: one with better verbal learning after 14 days without the number of participants given in the abstract [13], and effects at chance level in the scopolamine model [14]. No modern, replicated study.

  • partly supported

    “Piracetam helps in dementia”

    Benefit in the global clinical impression, not in specific cognitive tests [8]; for memory, no significant difference with very high heterogeneity [9].

  • not supported

    “Racetams use up acetylcholine, so you have to add choline”

    No study shows acetylcholine consumption. In old mice, the density of muscarinic receptors rose; concurrent choline administration did not change this effect [4].

  • partly supported

    “Piracetam is an AMPA receptor enhancer like the ampakines”

    Piracetam binds to the modulator region of the AMPA receptor binding domain, but only weakly and at several sites [3]; functional enhancement in humans has not been shown.

Pharmacokinetics

Absorption
After administration as an infusion or syrup in healthy people, nearly identical concentration curves in the blood [15].
Half-life
Elimination half-life 4.3 hours in healthy people [15].
Metabolism
Not described in the abstracts checked.
Entry into the brain
Not quantified in humans in the sources checked.

Legal status

Germany
Prescription-only as a medicinal product (AMVV Annex 1, entry “Piracetam”) [17]; German medicines register and indications not separately checked.
EU
Prescription-only medicinal product [16].
USA
not verified.
Other countries
In clinical use for decades; a 1999 review speaks of 25 years of clinical use [11]. The Cochrane review names UCB Pharma as the main distributor worldwide [8].

Related compounds

PhenylpiracetamderivativeEtiracetamanalog (German only)Levetiracetamanalog (German only)Aniracetamsame class (German only)Oxiracetamsame class (German only)Pramiracetamsame class (German only)Nefiracetamsame class (German only)

Open questions

  • Which mechanism explains the well-documented effect in cortical myoclonus?
  • Can the findings on receptor density and mitochondria be replicated by independent groups?
  • Does piracetam have a measurable effect on memory or attention in a sufficiently large randomized trial in healthy people?

References

  1. Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. 2005;11(2):169–82. doi:10.1111/j.1527-3458.2005.tb00268.x · PubMed
  2. Müller WE, Eckert GP, Eckert A. Piracetam: novelty in a unique mode of action. Pharmacopsychiatry. 1999;32 Suppl 1:2–9. doi:10.1055/s-2007-979230 · PubMed
  3. Ahmed AH, Oswald RE. Piracetam defines a new binding site for allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors. J Med Chem. 2010;53(5):2197–203. doi:10.1021/jm901905j · PubMed
  4. Pilch H, Müller WE. Piracetam elevates muscarinic cholinergic receptor density in the frontal cortex of aged but not of young mice. Psychopharmacology (Berl). 1988;94(1):74–8. doi:10.1007/BF00735884 · PubMed
  5. Cohen SA, Müller WE. Effects of piracetam on N-methyl-D-aspartate receptor properties in the aged mouse brain. Pharmacology. 1993;47(4):217–22. doi:10.1159/000139100 · PubMed
  6. Keil U, Scherping I, Hauptmann S, Schuessel K, Eckert A, Müller WE. Piracetam improves mitochondrial dysfunction following oxidative stress. Br J Pharmacol. 2006;147(2):199–208. doi:10.1038/sj.bjp.0706459 · PubMed
  7. Evers S, Grotemeyer KH. Piracetam and platelets – a review of laboratory and clinical data. Pharmacopsychiatry. 1999;32 Suppl 1:44–8. doi:10.1055/s-2007-979236 · PubMed
  8. Flicker L, Grimley Evans G. Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev. 2001;(2):CD001011. doi:10.1002/14651858.CD001011 · PubMed
  9. Gouhie FA, Barbosa KO, Cruz ABR, Wellichan MM, Zampolli TM. Cognitive effects of piracetam in adults with memory impairment: a systematic review and meta-analysis. Clin Neurol Neurosurg. 2024;243:108358. doi:10.1016/j.clineuro.2024.108358 · PubMed
  10. Ricci S, Celani MG, Cantisani TA, Righetti E. Piracetam for acute ischaemic stroke. Cochrane Database Syst Rev. 2012;(9):CD000419. doi:10.1002/14651858.CD000419.pub3 · PubMed
  11. De Reuck J, Van Vleymen B. The clinical safety of high-dose piracetam – its use in the treatment of acute stroke. Pharmacopsychiatry. 1999;32 Suppl 1:33–7. doi:10.1055/s-2007-979234 · PubMed
  12. Koskiniemi M, Van Vleymen B, Hakamies L, Lamusuo S, Taalas J. Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. J Neurol Neurosurg Psychiatry. 1998;64(3):344–8. doi:10.1136/jnnp.64.3.344 · PubMed
  13. Dimond SJ, Brouwers EM. Increase in the power of human memory in normal man through the use of drugs. Psychopharmacology (Berl). 1976;49(3):307–9. doi:10.1007/BF00426834 · PubMed
  14. Wesnes K, Anand R, Simpson P, Christmas L. The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers. J Psychopharmacol. 1990;4(4):219–32. doi:10.1177/026988119000400406 · PubMed
  15. Saletu B, Hitzenberger G, Grünberger J, Anderer P, Zyhlarz G, Linzmayer L, et al. Double-blind, placebo-controlled, pharmacokinetic and -dynamic studies with 2 new formulations of piracetam (infusion and sirup) under hypoxia in man. Int J Clin Pharmacol Ther. 1995;33(5):249–62. PubMed
  16. Vanhee C, Deconinck E, George M, Hansen A, Hackl A, Wollein U, et al. The occurrence of illicit smart drugs or nootropics in Europe and Australia and their associated dangers: results from a market surveillance study by 12 official medicines control laboratories. J Xenobiot. 2025;15(3):88. doi:10.3390/jox15030088 · PubMed
  17. Verordnung über die Verschreibungspflicht von Arzneimitteln (Arzneimittelverschreibungsverordnung – AMVV), Anlage 1 (zu § 1 Nr. 1 und § 5). Stand: zuletzt geändert durch Art. 1 V v. 19.5.2026 (BGBl. 2026 I Nr. 149). Bundesministerium der Justiz [Internet]. Abgerufen am 26.10.2026. Verfügbar unter: https://www.gesetze-im-internet.de/amvv/anlage_1.html (Eintrag „Piracetam“).
How this profile was checked

Last reviewed: 2026-10-26. All sources with a DOI or PMID were resolved automatically via Crossref or doi.org and PubMed.

Translated from the German profile (version of 2026-10-26); translation checked on 2026-10-26.

Checked

  • October 26, 2026 (decision n015, audit report E-20 question 14): `rx_referenz` set, `kategorie` remains Nootropikum. AMVV Annex 1 retrieved in full text (“gesetze-im-internet.de”, status: last amended by Art. 1 of the Ordinance of May 19, 2026, BGBl. 2026 I No. 149): entry “Piracetam” without exception or restriction [17]; the prescription requirement is now stated with a source in status.deutschland. The AMIce wording from the audit report was not adopted because no document view of a product with the status “authorized” or “renewed” was read (audit report, methodology 1).
  • All 15 DOIs resolved via Crossref and all 16 PMIDs via PubMed (checking script).
  • In the full text of [16]: “In the EU, piracetam is a prescription drug”.
  • Key figures checked against abstracts: low occupancy of several binding sites [3]; receptor density +30–40% [4] and +20% [5]; 100–1000 µM [6]; odds ratio 3.55 (2.45–5.16) [8]; 18 studies, n = 886, SMD 0.75 (−0.19 to 1.69), I² 96% [9]; three studies, n = 1002, about +31% deaths [10]; PASS n = 927, bleeding equally frequent [11]; n = 20 [12]; 7 vs. 14 days [13]; n = 26, chance level [14]; n = 18, t½ 4.3 h [15].
  • Full text (open access) of [3]: binding to GluA2 and GluA3, several positions on the dimer interface.
  • ClinicalTrials.gov: 20 entries for piracetam (October 23, 2026).
  • October 25, 2026, trade names (source per guideline section “Handelsnamen”, decision of October 25, 2026; according to status, piracetam is prescription-only in the EU): “Normabraïn” removed from synonyms. The name was not documented in the profile and is not in the EMA database under Article 57 (Article 57 product data, EMA/518502/2018 Rev. 90, data as of October 9, 2026, retrieved October 25, 2026; search for “normabr” as a substring without hits). Evidence for the remaining names in the same list: “Nootrop” (intravenous, piracetam) in Germany; “Nootropil” (oral) in 14 countries or territories (including Belgium, Italy, Poland, Sweden), not in Germany. Also listed for Germany is “Cebrotonin” (oral); not added because, as worded, the trade-name rule applies only to `kategorie` Arzneimittel. Products named after the active substance and the company not considered. The listing does not document the content of the authorization; status is unchanged.

Not verified

  • Authorization status not checked in medicines registers; the EU statement rests on the classification by European medicines control laboratories in the full text of [16]. Status in the US not verified.
  • Number of participants and control condition of the study [13] are not in the abstract.
  • Individual studies in the review on platelets [7] not checked one by one; evidence level 3 for this effect is an estimate.
  • Metabolism and cerebrospinal fluid penetration in humans not checked against primary sources.

No dosages, no sources of supply. This information does not replace medical advice.

Spotted an error or missing something?

Request a compound, suggest an improvement or report an error. Every message is read.

Type of message

The website stores nothing. The button opens your email app with a pre-filled message.